Meta-analysis of hematopoietic stem cell transplantation in major histocompatibility complex class II deficiency.

Pediatric Transplantation
Lina Maria Castano-JaramilloAndres Felipe Escobar-Gonzalez

Abstract

Major histocompatibility complex class II deficiency is a rare case of PID. Specific recommendations for hematopoietic stem cell transplant, the only curative treatment option, are still lacking. This meta-analysis aims to identify the factors associated with better prognosis in these patients. Thirteen articles reporting 63 patients with major histocompatibility complex class II deficiency that underwent hematopoietic stem cell transplant were included. The median age for hematopoietic stem cell transplant was 18 months. The most common source of transplant was bone marrow, with alternative sources as umbilical cord blood emerging during recent years. The highest proportion of engraftment was seen with umbilical cord. Engraftment was higher in patients with matched donors, with better overall survival in patients with reduced-intensity conditioning. Graft-vs-host disease developed in 65% of the patients, with grades I-II being the most frequently encountered. There was a higher mortality in patients with myeloablative conditioning and no engraftment. There was an inverse correlation between survival and stage of graft-vs-host disease. The main cause of mortality was infectious disease, mostly secondary to viral infections. Ide...Continue Reading

References

Sep 22, 2000·Archives of Disease in Childhood·M A SaleemP A Veys
Aug 14, 2001·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·E GluckmanS Chevret
Jun 22, 2005·Bone Marrow Transplantation·A BhattacharyaA R Gennery
Sep 11, 2007·The Journal of Allergy and Clinical Immunology·Evelina MazzolariLuigi D Notarangelo
Oct 3, 2009·British Journal of Haematology·Angela R Smith, John E Wagner
Jan 19, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hamoud Al-MousaHassan El-Solh
Feb 2, 2010·Immunology and Allergy Clinics of North America·Paul Veys
Aug 3, 2010·The Journal of Allergy and Clinical Immunology·Andrew R GenneryUNKNOWN European Society for Immunodeficiency
Sep 20, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yu WangXiao-Jun Huang
Oct 18, 2011·Current Opinion in Pediatrics·Jennifer M Puck
Sep 25, 2012·Bone Marrow Transplantation·T N SmallM Sparber-Sauer
Jul 9, 2014·The Journal of Allergy and Clinical Immunology·Suheir Hanna, Amos Etzioni
Jul 31, 2014·The New England Journal of Medicine·Sung-Yun PaiRichard J O'Reilly
Aug 21, 2014·JAMA : the Journal of the American Medical Association·Antonia KwanVincent R Bonagura
Oct 30, 2014·Journal of Pediatric Hematology/oncology·Michael E Kallen, Sheeja T Pullarkat
May 31, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jessica WardWilliam T Tse
Apr 30, 2017·Stem Cells Translational Medicine·Karen Ballen
Jan 26, 2018·The Journal of Allergy and Clinical Immunology·Reem ElfekyPaul Veys
Dec 13, 2019·Frontiers in Immunology·Franco AversaAndrea Velardi
Jan 11, 2020·Frontiers in Pediatrics·Su Han LumAndrew R Gennery

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.